Unfortunately all the trials came back to me and said we have to go through our doctors to pursue such trials 😢...

I understand your frustration with the trial access barriers and your determination to find treatment options for Alan. Let me address the dendritic cell therapy you're pursuing and provide some important context.

About Dendritic Cell Therapy for Glioblastoma

What the Evidence Shows:

According to information from brain cancer treatment experts, dendritic cell vaccines (like DCVax) have shown mixed but potentially meaningful results for glioblastoma:

The Reality:

• By itself, it provided only a small increase in median survival and "didn't help the typical person"
• However, it doubled the percentage of long-term survivors - creating what's called a "long tail" on survival curves
• Importantly, patients experienced minimal to no side effects
• The benefit is described as "adding chances" rather than being a definitive solution

Most Promising Approach: Early results suggest dendritic cell therapy works better in combination with immune enhancers (like checkpoint inhibitors such as Keytruda/pembrolizumab). Small trials combining these approaches have shown more encouraging survival curves for recurrent glioblastoma.

Regarding Your Specific Situation

Positive Aspects:

1. Low risk: Minimal side effects mean it won't harm Alan's quality of life
2. Faster than NGS testing: You mentioned it's quicker than Cegat processing
3. Maintains options: Unlike some treatments, it shouldn't exclude Alan from future trials
4. Alan's excellent functional status (ECOG PS 0) makes him a good candidate

Critical Concerns:

1. As monotherapy (alone), the evidence suggests modest benefit for most patients
2. Cost-effectiveness: You mentioned it's costly - ensure you understand the full treatment schedule and total investment
3. Combination approach: Ask the German clinic if they can combine it with other immune-enhancing treatments

What You Should Ask the German Clinic

Before proceeding on November 11th:

1. Treatment protocol:

   • How many injections total?
   • What's the schedule?
   • Total cost for complete treatment course?

2. Combination options:

   • Can they add checkpoint inhibitors (like pembrolizumab)?
   • What about other immune enhancers?
   • According to NCCN Guidelines, combination immunotherapy approaches are being actively studied for recurrent glioblastoma

3. Trial eligibility:

   • Will this treatment exclude Alan from future clinical trials?
   • Can they help coordinate with trials that combine dendritic cell therapy with other agents?

Regarding Avastin (Bevacizumab)

Important Context: According to NCCN Guidelines and American Cancer Society recommendations, bevacizumab (Avastin) is an FDA-approved option for recurrent glioblastoma. It can:

• Reduce tumor swelling and symptoms
• Improve quality of life
• Potentially extend progression-free survival

Your Action Items:

1. Second opinion appointment: Excellent decision - use this to:

   • Request the Avastin letter
   • Ask about combining Avastin with dendritic cell therapy
   • Discuss clinical trial options they can facilitate

2. Be direct: Explain that your current team said "there's nothing to do" but you need them to support accessing available treatments like Avastin

My Honest Assessment

The dendritic cell therapy is reasonable given:

• Alan's excellent functional status
• Limited side effects
• Your need to feel you're doing something active
• The possibility of being a long-term responder

BUT - it's not sufficient as a standalone approach. You need to:

1. Continue pursuing the second opinion - critical for accessing trials and getting the Avastin letter
2. Push for combination approaches - dendritic cells work better with other immunotherapies
3. Complete the NGS testing through Protean BioCare - this could identify targetable mutations
4. Consider adding:
   • Tumor Treating Fields (Optune) if available in Italy
   • Repurposed drugs (gabapentin, fluoxetine) per UCSF protocols
   • Imipramine + bevacizumab combination

Bottom Line

The dendritic cell therapy adds a chance but shouldn't be your only strategy. Use your second opinion appointment to build a comprehensive treatment plan that includes:

• Dendritic cell therapy (low risk, potential benefit)
• Avastin (proven benefit for recurrent GBM)
• Clinical trial access (your best chance for meaningful impact)
• Molecular testing results to guide targeted therapy

You're doing the right thing by being proactive. Don't let anyone make you feel otherwise. Alan's excellent functional status means he deserves aggressive treatment attempts.

Would you like help preparing specific questions for your second opinion appointment on November 11th?